Mallinckrodt plc (NYSE American: MNK) has made a significant disclosure in a regulatory filing with the U.S. Securities and Exchange Commission (SEC). The company has received unsolicited letters from various parties holding substantial positions across its capital structure.

The first letter, received on May 17, 2023, addresses several matters, including the Holders' perspectives on Mallinckrodt's financial position. In response to the company's financial responsibilities, particularly the $200 million payment required by the opioid settlement to be made to the Opioid Master Disbursement Trust II on June 16, 2023, certain Holders have urged the company's board of directors and management team to evaluate alternative options.

Among these alternatives, certain Holders have proposed transactions to be implemented through a filing under Chapter 11 of the U.S. Bankruptcy Code. These transactions may involve a sale of assets in accordance with Section 363 of the Bankruptcy Code. On the other hand, other Holders and interested parties have put forth alternative transactions that do not require a bankruptcy filing.

$MNK was trading at $1.90 in pre-market, down $0.55 (22.45%).

Amedisys, Inc. (Nasdaq: AMED) has made a significant announcement concerning an unsolicited proposal received from Optum, a prominent health services company. On May 26, 2023, Optum put forward a compelling offer to acquire all outstanding shares of Amedisys' common stock in an all-cash transaction, proposing a price of $100 per share.

It is worth noting that Amedisys had previously entered into an all-stock merger agreement with Option Care Health, Inc. (Nasdaq: OPCH).

Taking their fiduciary responsibilities seriously and in full compliance with the terms and conditions stipulated in the existing merger agreement with Option Care Health, Amedisys' Board of Directors engaged external legal counsel and financial advisors to meticulously evaluate Optum's proposal, finally determining that Optum's proposal holds the potential to qualify as an "Amedisys Superior Proposal"

Amedisys has recently entered into a confidentiality agreement with Optum and is actively engaging in exploratory discussions with Optum to gain further insights and assess the merits of their proposal.

Following the announcement, $AMED experienced a significant surge in pre-market trading, reaching $91.50 with a notable increase of $12.03 (+15.14%)

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)